The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous su...
To compare pramipexole to escitalopram in the treatment of major depressive disorder in people living with HIV.
This study will evaluate how well, how safe, and how long-lasting a treatment called CAB LA + RPV LA is for people with HIV who still have detectable virus levels even though they are taking oral ART. The study will also consider feedback from patients on their experience with this treatment.
The purpose of this study is to see if an experimental vaccine called CH505 TF chTrimer is safe and well tolerated in people living with human immunodeficiency virus (HIV) and to see if it will help the body's immune system respond to HIV.
The goal of this study is to create a national network to study individuals at-risk for developing Rheumatoid Arthritis. This will be done through two objectives Objective #1) Establish the infrastructure to identify and follow antibodies to citrullinated protein antigens (ACPA) positive individuals who have been identified through routine care at rheumatology clinical practices or previously e...
To evaluate the safety and tolerability of benralizumab
The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to < 6 mg/dL for at least 80% of the time.
The goal of the Accelerating Medicines Partnership (AMP) research study is to better understand the molecular and cellular characteristics of Rheumatoid Arthritis (RA) to help develop better therapies for people with RA.
To evaluate the efficacy of GS-5718 versus placebo-to-match (PTM) in reducing skin disease activity for participants with CLE with or without systemic lupus erythematosus. To evaluate the efficacy of GS-5718 versus PTM in reducing skin disease activity for participants with CLE with or without SLE. To evaluate the safety and tolerability of GS-5178 in participants with CLE with or without SLE.
For Period 1, the primary objective is to evaluate the efficacy and safety of upadacitinib and adalimumab, in adult subjects on background MTX, following an inadequate response or intolerance to a single TNFi. For Period 2, the objective is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib and adalimumab in subjects who have completed Period 1.
In this study, we plan to learn about the causes of rheumatoid arthritis (RA) and about lung disease in RA. RA is an autoimmune disease that can cause arthritis, and in some people, RA can also be related to lung disease called ‘interstitial lung disease’ (or ILD).
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
To learn more about lung disease and risk of lung disease in early RA.
To evaluate the health and wellbeing of women living with HIV of reproductive age utilizing innovative epidemiologic study designs and cost-effective methods for enrollment, follow-up and data collection
This study involves chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their disease. In autoimmune diseases such as rheumatoid arthritis (RA), certain parts of the immune system are overactive, leading to inflammation. A subtype of immune cells, called regulatory T cells (Tregs), normally help to reduce ...
The primary objective of the current study is to validate the performance of the current ASAS classification criteria in a prospective, combined cohort of patients presenting with undiagnosed current back pain.
The primary objective of this study is to demonstrate efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity.
To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is referred to as an ATI (analytical treatment interruption).
To longitudinally study individuals at risk for spondyloarthritis and spondyloarthritis associated diseases.
To test CAR T cell therapy (a type of therapy made from one's own immune cells) for refractory lupus nephritis
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis ...
Primary objective is to evaluate the effectiveness of cenerimod 4mg at reducing disease activity compared to placebo. The secondary objective is to evaluate the effect of cenerimod 4mg to control the disease compared to placebo. The safety objective is to evaluate the safety and tolerability of cenerimod 4mg.
